Facility at NUS Medicine targets precision geromedicine and a faster, more effective path from lab to clinic.
Singapore has made another decisive move in the global race to extend healthspan, unveiling a new Clinical Trial Centre at NUS Medicine dedicated to translating geroscience into clinical practice. Spanning 350 square meters and equipped with state-of-the-art facilities, the center has been designed as a hub for precision geromedicine – an emerging field that combines biomarker-driven diagnostics, digital monitoring and systems biology to tailor interventions to an individual’s biological age and unique health trajectory. Its remit is ambitious: to generate robust evidence that moves geroscience from promising theory to practical medicine while training the next generation of longevity-focused clinician-scientists.
Longevity.Technology: Singapore’s latest investment in healthy longevity is not just another ribbon-cutting ceremony – it’s a clear statement of intent. The new Clinical Trial Centre at NUS Medicine is an elegant fusion of infrastructure, intellect and ambition; a facility purpose-built to translate the theoretical promise of geroscience into clinical reality. In bringing precision geromedicine out of the lab and into the clinic, NUS is addressing one of the field’s enduring weaknesses – the gap between biomarker discovery and real-world intervention. It’s an audacious play for leadership in a space still dominated by Western institutions, and one that signals a shift in the center of gravity for longevity innovation toward Asia’s most future-focused city-state.
The Centre’s multimodal, systems-level approach – blending multi-omics data, organ-level diagnostics and behavioral insights – offers the kind of integrated framework longevity research has long needed but rarely achieved. By embedding clinician training and patient engagement within the same ecosystem, NUS is creating not only trials, but a talent pipeline and, crucially, a societal narrative around aging well. This is geroscience done with foresight: data-rich, globally networked and unapologetically translational. The rest of the world would do well to pay attention – because Singapore, it seems, isn’t just preparing to age gracefully, but to redefine what aging gracefully means.
A new model for precision geromedicine
At the heart of the Centre’s work is a shift toward what NUS Medicine calls precision geromedicine – a personalized, biomarker-based approach to preventing age-related decline and maintaining function throughout the adult lifespan. The facility has been purpose-built for scale and rigor, capable of running multiple clinical trials simultaneously while collecting and processing biological samples on-site – a design that should improve reproducibility and allow the kind of large-scale, system-wide analyses that have often been missing from geroscience research.
Professor Andrea Maier, Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research and Director of the Academy for Healthy Longevity, explained that an interdisciplinary gerodiagnostics framework that assesses biological age and the function of multiple physiological and organ systems sits at the core of the Academy’s approach.
“The framework enables standardised evaluations across different levels, from molecular, clinical, psychological, behavioural, to social biomarkers of ageing, providing comprehensive, system wide analyses of participant health and intervention impact,” she said. “With the Centre, we aim to generate high-quality evidence needed to extend healthspan, while training a new cadre of clinician-scientists to translate geroscience from bench to bedside.”
The Centre’s capabilities include ophthalmological and dental evaluations, sleep and behavior monitoring, full-body DEXA scanning and an investigative product repository – in other words, a comprehensive suite designed to capture the complexity of aging in real time. Such integration of clinical and molecular data could help standardize how biological age is measured, a persistent challenge in the field.
Multimodal trials and the complexity of aging
Traditional clinical trials tend to isolate single interventions; however, aging is a network phenomenon involving multiple physiological systems interacting over decades. The Centre’s approach embraces this complexity. NUS Medicine is hoping to pioneer a new generation of multimodal clinical trials that combine interventions and measurements across multiple organ systems, capturing the interplay between biological pathways to uncover synergistic effects rather than isolated outcomes.
“Our approach to move towards multimodal trials combining interventions and measurements across multiple organ systems simultaneously allow us to understand and tailor interventions to achieve synergistic outcomes,” Maier added.
Among these are: PROMETHEUS, a precision geromedicine feasibility trial combining exercise, supplements and lifestyle coaching; the SIRT6 Activator trial exploring the DNA-repair potential of fucoidan from brown seaweed; and CEDIRA, a double-blind study examining how multivitamins might influence biological age in adults whose biological markers outpace their chronological years. Together, these studies represent a comprehensive exploration of interventions targeting resilience, rather than simply disease.
Training the next generation
Beyond research, the Centre is designed as a training ground, with an integrated educational model that immerses students and clinicians-in-training in active trials. Participants will gain hands-on experience in data collection, biological sampling and translational research methods – a practical framework intended to bridge the gap between classroom knowledge and clinical application.
It’s a necessary move. As the longevity sector grows, demand is rising for professionals fluent in both clinical practice and the biology of aging. By embedding education directly within the clinical infrastructure, NUS is addressing what may soon become a global skills shortage – and in doing so, creating a workforce capable of scaling preventive, personalized care.
Collaboration as a catalyst
The Academy’s network of partners reads like a microcosm of the broader longevity ecosystem: industry leaders such as Abbott, Haleon, L’Oréal, and Danone; start-ups like AMILI and DoNotAge; and patient advocacy organizations including APOS. The inclusion of both corporate and patient voices reflects a pragmatic understanding that healthy longevity depends on cross-sector alignment – from consumer health to regulation to public engagement.
Professor Chong Yap Seng, Dean of NUS Medicine observed that while Singaporeans are living longer, the last 10 years of life are often spent in ill health.
“The Clinical Trial Centre strengthens our ability to translate our research into real-world solutions that improve care, policy, and population health,” he said. “By integrating geroscience research and education into one facility, we are building the talent and the evidence base required to benefit our aging communities here and around the world.” His comments point to the Centre’s dual purpose – advancing science while shaping the policy and practice frameworks that will support longer, healthier lives.
The Clinical Trial Centre strengthens our ability to translate our research into real-world solutions that improve care, policy, and population health. By integrating geroscience research and education into one facility, we are building the talent and the evidence base required to benefit our ageing communities here and around the world.
The age of convergence
The launch of the Clinical Trial Centre feels emblematic of a broader convergence happening across the longevity field: between biology and data science, between healthcare and policy and between the local and global. Singapore’s initiative demonstrates how infrastructure, education and collaboration can come together to form a blueprint for translating geroscience into public health impact.
Aging is universal; how societies respond to it is not. And as the race to extend healthspan accelerates, Singapore’s quiet precision may yet prove its most powerful advantage.
Images courtesy of NUS Singapore. Main image shows NUS Medicine’s Academy for Healthy Longevity team, outside their new clinical trial center. From L to R: Mr Shivaji Rikka, Ms Jane Ong, Professor Andrea Maier, Dr Dotou Mazzarine and Dr Ajla Hodzic Kuerec.
